Corbus Pharmaceuticals Holdings, Inc. (CRBP) Income Statement Analysis

See more : Sahathai Printing & Packaging Public Company Limited (STP.BK) Income Statement Analysis – Financial Results

Complete financial analysis of Corbus Pharmaceuticals Holdings, Inc. (CRBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Corbus Pharmaceuticals Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

The Hain Celestial Group, Inc. (0J2I.L) Income Statement Analysis – Financial Results
Jiangnan Mould & Plastic Technology Co., Ltd. (000700.SZ) Income Statement Analysis – Financial Results
RaffAello-Astrum Financial Holdings Limited (8333.HK) Income Statement Analysis – Financial Results
Plaza Retail REIT (PLZ-UN.TO) Income Statement Analysis – Financial Results
Quest Oil Corporation (QOIL) Income Statement Analysis – Financial Results

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.corbuspharma.com

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	0.00	0.00	881.71K	3.94M	36.14M	4.82M	2.44M	1.91M	648.38K	0.00	0.00	0.00
Cost of Revenue	31.17M	1.49M	1.64M	98.27K	89.60K	48.61M	26.04M	15.44M	5.89M	1.26M	0.00	0.00
Gross Profit	-31.17M	-1.49M	-757.53K	3.84M	36.05M	-43.79M	-23.60M	-13.53M	-5.24M	-1.26M	0.00	0.00
Gross Profit Ratio	0.00%	0.00%	-85.92%	97.50%	99.75%	-908.11%	-967.09%	-707.60%	-808.21%	0.00%	0.00%	0.00%
Research & Development	31.17M	16.14M	36.45M	98.27M	89.60M	48.61M	26.04M	15.44M	5.89M	1.26M	210.67K	575.09
General & Administrative	13.91M	18.70M	20.43M	28.48M	23.64M	12.96M	8.96M	6.46M	3.61M	1.39M	346.61K	289.05
Selling & Marketing	-641.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	13.27M	18.70M	20.43M	28.48M	23.64M	12.96M	8.96M	6.46M	3.61M	1.39M	346.61K	289.05
Other Expenses	-30.53M	-48.77K	11.90M	13.27M	4.58M	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	13.91M	34.84M	56.87M	126.75M	113.25M	61.57M	35.00M	21.90M	9.50M	2.65M	557.28K	827.22
Cost & Expenses	45.08M	34.84M	56.87M	126.75M	113.25M	61.57M	35.00M	21.90M	9.50M	2.65M	557.28K	827.22
Interest Income	0.00	0.00	1.83K	1.03K	1.23M	982.78K	183.11K	477.00	3.42K	2.12K	754.00	59.74
Interest Expense	2.92M	2.13M	1.83M	1.03M	19.03K	0.00	183.11K	0.00	2.44K	24.02K	45.11K	0.00
Depreciation & Amortization	640.60K	1.49M	1.64M	1.69M	1.23M	493.94K	255.65K	87.66K	43.94K	10.41K	754.00	824.15
EBITDA	-44.44M	-38.73M	-54.97M	-121.69M	-76.37M	-56.25M	-32.31M	-19.90M	-8.81M	-2.64M	-556.52K	-62.81
EBITDA Ratio	0.00%	0.00%	-6,381.74%	-3,101.40%	-212.89%	-1,178.71%	-1,332.72%	-1,040.23%	-1,358.20%	0.00%	0.00%	0.00%
Operating Income	-45.08M	-39.84M	-55.99M	-122.81M	-77.10M	-56.75M	-32.56M	-19.99M	-8.85M	-2.65M	-557.28K	-824.15
Operating Income Ratio	0.00%	0.00%	-6,350.09%	-3,119.20%	-213.33%	-1,176.78%	-1,334.43%	-1,045.56%	-1,365.51%	0.00%	0.00%	0.00%
Total Other Income/Expenses	473.99K	-2.51M	10.35M	11.54M	5.65M	1.08M	141.20K	-13.62K	2.95K	106.69K	-45.07K	-62.81
Income Before Tax	-44.60M	-42.35M	-45.64M	-111.27M	-71.45M	-55.67M	-32.42M	-20.00M	-8.85M	-2.54M	-602.35K	-886.96
Income Before Tax Ratio	0.00%	0.00%	-5,176.38%	-2,826.08%	-197.69%	-1,154.48%	-1,328.65%	-1,046.27%	-1,365.05%	0.00%	0.00%	0.00%
Income Tax Expense	0.00	13.49M	-87.84K	35.05K	-2.30M	1.08M	-396.86K	13.62K	2.44K	24.02K	44.36K	-62.81
Net Income	-44.60M	-55.83M	-45.55M	-111.30M	-69.15M	-55.67M	-32.42M	-20.00M	-8.85M	-2.54M	-602.35K	-886.96
Net Income Ratio	0.00%	0.00%	-5,166.42%	-2,826.97%	-191.33%	-1,154.48%	-1,328.65%	-1,046.27%	-1,365.05%	0.00%	0.00%	0.00%
EPS	-10.31	-13.39	-11.11	-42.74	-32.47	-29.30	-19.38	-14.58	-8.47	-3.78	-0.70	-3.82
EPS Diluted	-10.31	-13.39	-11.11	-42.74	-32.47	-29.30	-19.38	-14.58	-8.47	-3.78	-0.70	-3.82
Weighted Avg Shares Out	4.33M	4.17M	4.10M	2.60M	2.13M	1.90M	1.67M	1.37M	1.05M	672.00K	860.06K	232.00
Weighted Avg Shares Out (Dil)	4.33M	4.17M	4.10M	2.60M	2.13M	1.90M	1.67M	1.37M	1.05M	672.00K	860.06K	232.16

Recap: Corbus Pharmaceuticals Q2 Earnings

August 12, 2021benzinga.com

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) decreased 1.5% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 71.15% year over year to ($0.15), which missed the estimate of ($0.12).

Corbus Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Updates

August 12, 2021globenewswire.com

Norwood, MA, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company, today provided corporate updates and reported financial results for the second quarter of 2021.

Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

July 29, 2021zacks.com

Corbus Pharmaceuticals (CRBP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist

July 8, 2021pennystocks.com

Why investors are watching these 7 penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 7 For Your Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Pot Stocks in Focus: Cannabis-Based Pharmaceutical Trials

June 25, 2021schaeffersresearch.com

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.

Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

June 24, 2021globenewswire.com

Norwood, MA, June 24, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an immunology company developing innovative medicines that target inflammation, fibrosis, metabolism and immuno-oncology, today announced topline results from the Phase 3 D ETER M INE...